AGPU

SEC Filing Summary: BioDrain Medical, Inc. (10-Q)

Business Context and Reporting Period

Company: BioDrain Medical, Inc. (Note: Metadata listed "Axe Compute Inc." is incorrect; filing is for BioDrain Medical, Inc.)
Period: Quarterly period ended March 31, 2011
Status: Development stage company; smaller reporting company.
Operations: Developing an environmentally safe Fluid Management System (FMS) for the collection and disposal of infectious fluids from surgical procedures. The company received FDA 510(k) clearance on April 1, 2009, but has not yet achieved significant commercial sales volume.

Key Financial Metrics

Debt & Liquidity: The company holds significant convertible debt and accounts payable. Current liabilities include $581,467 in current portion of convertible debt and $653,114 in accounts payable. Cash flow from financing activities provided $689,291 in Q1 2011, primarily from proceeds of long-term and convertible debt and issuance of common stock.

Material Changes vs. Prior Period

• Revenue: Revenue dropped to $0 in Q1 2011 from $288 in Q1 2010. The prior period revenue was from a beta site customer purchasing disposable supplies.
• Net Loss: Net loss improved (decreased) by approximately $274,000 compared to Q1 2010, primarily due to a significant reduction in stock-based consulting expenses ($85,916 in Q1 2011 vs. $541,647 in Q1 2010).
• Interest Expense: Increased to $57,892 from $14,279 due to higher levels of interest-bearing debt and amortization of debt discounts associated with new convertible notes.
• Cash Position: Cash increased significantly from $9,383 at year-end 2010 to $331,269 at March 31, 2011, driven by successful private placements of equity and convertible debt.
• Liabilities: Current liabilities increased, notably the current portion of convertible debt which rose from $56,000 to $581,467.

Guidance, Outlook, and Risks

Capital Needs: Management estimates a need for approximately $2 million in capital to operate for the next 12 months. The company engaged a new investment banker in May 2011 to raise this amount. Failure to raise capital could force a reduction or suspension of operations.

Going Concern: The filing includes a "substantial doubt" disclosure regarding the company's ability to continue as a going concern due to recurring losses and accumulated deficit.

Outlook: The company expects operations expenses to increase as it scales up sales and marketing efforts following FDA clearance. Future profitability depends on converting beta site evaluations into billable orders.

Risks:

• Inability to raise sufficient additional capital.
• Substantial dilution to existing shareholders if equity financing is pursued.
• Dependence on third-party contract manufacturers and independent sales representatives.
• Volatility in the valuation of equity-linked financial instruments (warrants).

Investor Verification Checklist

• Capital Runway: Verify the status of the $2 million fundraising effort initiated in May 2011 and the company's ability to meet obligations beyond July 2011.
• Debt Conversion Terms: Review the conversion prices of outstanding convertible notes (ranging from $0.084 to $0.35) to assess potential dilution upon conversion.
• Revenue Pipeline: Confirm the status of hospital evaluations for the FMS unit and the timeline for converting these into billable orders.
• Related Party Transactions: Examine the significant portion of debt held by officers, their parents, and related entities (Note 7 and Note 10).
• Warrant Liability: Monitor the fair value adjustments of equity-linked instruments, which caused a $4,728 gain in Q1 2011 but have historically caused significant volatility in net income.